Panacea Biotec Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of Panacea Biotec reported to Rs 0.52 crore in the quarter ended March 2026 as against net loss of Rs 1.89 crore during the previous quarter ended March 2025. Sales rose 25.82% to Rs 166.75 crore in the quarter ended March 2026 as against Rs 132.53 crore during the previous quarter ended March 2025.

For the full year,net loss reported to Rs 5.37 crore in the year ended March 2026 as against net loss of Rs 8.37 crore during the previous year ended March 2025. Sales rose 14.43% to Rs 639.77 crore in the year ended March 2026 as against Rs 559.09 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Securities in F&O Ban:

Sammaan Capital and Steel Authority of India shares are banned from F&O trading on 13 April 2026.

Result Today:

ICICI Prudential Asset Management Company, Just Dial, Swaraj Engines, Innovision, Parin Enterprises, Indbank Housing and Continental Controls will announce their quarterly earnings today.

IPO Update:

Om Power reported 0.71x subscription on Day 2

Om Power?s initial public offering (IPO) was subscribed 0.71 times overall on Day 2 (as of 5:00 PM), with Qualified Institutional Buyers (QIBs) subscribing 1.18 times, the retail portion at 0.58 times, and Non-Institutional Investors (NIIs) at 0.38 times.

Stocks to Watch:

Panacea Biotec announced that it has received a letter of award (LoA) worth Rs 20.79 crore from Central Medical Services Society, under the Ministry of Health and Family Welfare, Government of India.

Advance Agrolife announced that it has received a letter of intent (LoI) worth Rs 30.37 crore from National Fertilizers for the supply of various agrochemicals.

Zaggle Prepaid Ocean Services announced that it has entered into an agreement with Generali Central Insurance Company (formerly known as Future Generali India Insurance Company Limited) to provide its Zaggle Zoyer platform.

Emerald Leisures said that it has received a letter of intent (LoI) for the development of a residential redevelopment project at Swastik Park, Chembur in Mumbai, with an estimated revenue potential of around Rs 600 crore.

Larsen & Toubro said its real estate arm, L&T Realty Properties, has acquired a 100% stake in International Green Scapes for Rs 1,123 crore in an all-cash deal, as it looks to expand its residential portfolio in Gurugram.

Airfloa Rail Technology said that it has secured a domestic order worth Rs 1.25 crore from Rail Coach Factory Kapurthala for the supply of luggage rack modules for LHB non-AC and AC chair car coaches.

Blue Dart Express reported a low-severity cyber security incident within its parent group. The company said the incident involved phishing and impersonation exposure. It clarified that no sensitive data was breached and no customer or business information was impacted.

Swiggy?s Co-founder Nandan Reddy has stepped down to pursue personal projects, while Chief Growth Officer Phani Kishan and Group CFO Rahul Bothra will join the board as Executive Directors.

Laxmi Organic announced that it has appointed Harshvardhan Goenka as Interim CFO following the resignation of Mahadeo Karnik.

LIC Housing Finance announced that it has appointed Sanjay Dayal as its Chief Operating Officer (COO).

As per the terms, the company will supply Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents (Td Vaccine) in multiple tranches. The supplies are scheduled to commence from September/October 2026 and continue till November/December 2028.

The company clarified that the order has been awarded by a domestic entity and is in the nature of vaccine supply. It further stated that neither its promoters nor promoter group entities have any interest in the awarding authority, and the transaction does not fall under related-party transactions.

Panacea Biotec is a research-based biotechnology company engaged in the business of research, development, manufacture, and marketing vaccines in India and international markets.

The company reported a consolidated net loss of Rs 7.36 crore in Q3 FY26 as against a net profit of Rs 9.65 crore in Q3 FY25. Revenue from operations declined 8.4% year on year to Rs 99.31 crore in Q3 FY26.

Shares of Panacea Biotec rose 1.23% to end at Rs 326 on 10 April 2026.